Fat-containing hepatocellular carcinoma in patients with cirrhosis: proposal of a diagnostic modification regarding enhancement characteristics.
Carcinoma, hepatocellular
Fatty
Liver cirrhosis
Liver neoplasms
Magnetic resonance imaging
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
26
08
2022
accepted:
03
08
2023
revised:
28
07
2023
pubmed:
11
10
2023
medline:
11
10
2023
entrez:
10
10
2023
Statut:
ppublish
Résumé
The aim of this study was to develop and validate an algorithm for the non-invasive diagnosis of these fat-containing HCCs. Eighty-four cirrhotic patients with 77 fat-containing HCCs and 11 non-HCC fat-containing nodules were retrospectively included. All MRIs were reviewed; nodule characteristics, European Association for the Study of the Liver (EASL) and LI-RADS classifications, and survival were collected. One of the major features of LI-RADS v2018 (non-rim-like arterial phase hyperenhancement [APHE]) was changed to include different enhancing patterns at arterial phase and a new fat-LI-RADS algorithm was created for fat-containing nodules in cirrhosis. Its diagnostic performance was evaluated in both a derivation and external validation cohort (external cohort including 58 fat-containing HCCs and 10 non-HCC fat nodules). Reproducibility of this new algorithm was assessed. In the derivation cohort, 54/77 (70.1%) fat-containing HCCs had APHE, 62/77 (80.5%) had enhancement compared to the nodule itself at arterial phase (APE), 43/77 (55.8%) had washout, and 20/77 (26.0%) had an enhancing capsule. EASL and LI-RADS had a sensitivity of 37.7% (29/77) and 36.4% (28/77), respectively, for the diagnosis of fat-containing HCC and both had a specificity of 100% (11/11). The new fat-LI-RADS algorithm increased sensitivity to 50.6% (39/77) without decreasing the specificity of 100% (11/11). The validation cohort confirmed the increased sensitivity, with a slight decrease in specificity. The concordance for the diagnosis of HCC for fat-LR5 was 85.3% (58/68). The new fat-LI-RADS algorithm proposed here significantly improves the performance of the non-invasive diagnosis of fat-containing HCC and thus could reduce the number of biopsies conducted for fat-containing HCCs. The European Association for the Study of the Liver and LI-RADS guidelines are poorly sensitive for the diagnosis of fat-containing HCC, mainly because of the low rate of arterial phase hyperenhancement (APHE) displayed by fat-containing HCC. Using all types of enhancement instead of APHE improves sensitivity of LI-RADS. • Fat-containing HCCs on MRI account for 7.5% of HCCs and have different imaging characteristics from non-fatty HCCs. • The European Association for the Study of the Liver and LI-RADS algorithms for the non-invasive diagnosis of HCC have low sensitivity for the diagnosis of fat-containing HCC with MRI (37.7% and 36.4%, respectively). • The new fat-LI-RADS, which includes a slight modification of the "arterial enhancement" criterion, improves the sensitivity for the diagnosis of fat-containing HCC using MRI, without degrading the specificity.
Identifiants
pubmed: 37816923
doi: 10.1007/s00330-023-10236-8
pii: 10.1007/s00330-023-10236-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2283-2293Informations de copyright
© 2023. The Author(s), under exclusive licence to European Society of Radiology.
Références
Chan AWH, Yu S, Yu Y-H et al (2016) Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. Histopathology 69:971–984
doi: 10.1111/his.13029
pubmed: 27380543
Salomao M, Remotti H, Vaughan R, Siegel A, Lefkowitch J, Klein Moreira R (2012) The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43:737–746
doi: 10.1016/j.humpath.2011.07.005
pubmed: 22018903
Jain D, Nayak NC, Kumaran V, Saigal S (2013) Steatohepatitic hepatocellular carcinoma, a morphologic indicator of associated metabolic risk factors: a study from India. Arch Pathol Lab Med 137:961–966
doi: 10.5858/arpa.2012-0048-OA
pubmed: 23808468
Kutami R, Nakashima Y, Nakashima O, Shiota K, Kojiro M (2000) Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33:282–289
doi: 10.1016/S0168-8278(00)80369-4
pubmed: 10952246
Yeh MM, Liu Y, Torbenson M (2015) Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. Hum Pathol 46:1769–1775
doi: 10.1016/j.humpath.2015.07.018
pubmed: 26410018
Shibahara J, Ando S, Sakamoto Y, Kokudo N, Fukayama M (2014) Hepatocellular carcinoma with steatohepatitic features: a clinicopathological study of Japanese patients. Histopathology 64:951–962
doi: 10.1111/his.12343
pubmed: 24898917
Salomao M, Yu WM, Brown RS, Emond JC, Lefkowitch JH (2010) Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34:1630–1636
doi: 10.1097/PAS.0b013e3181f31caa
pubmed: 20975341
Olofson AM, Gonzalo DH, Chang M, Liu X (2018) Steatohepatitic variant of hepatocellular carcinoma: a focused review. Gastroenterol Res 11:391–396
doi: 10.14740/gr1110
Pokharel SS, Macura KJ, Kamel IR, Zaheer A (2013) Current MR imaging lipid detection techniques for diagnosis of lesions in the abdomen and pelvis. Radiographics 33:681–702
doi: 10.1148/rg.333125068
pubmed: 23674769
Galle PR, Forner A, Llovet JM et al (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
doi: 10.1016/j.jhep.2018.03.019
Coty J-B, Paisant A, Esvan M et al (2020) A proposal for a useful algorithm to diagnose small hepatocellular carcinoma on MRI. Eur J Gastroenterol Hepatol 32:74–79
doi: 10.1097/MEG.0000000000001476
pubmed: 31211723
Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830
doi: 10.1148/radiol.2018181494
pubmed: 30251931
Costa AF, Thipphavong S, Arnason T, Stueck AE, Clarke SE (2018) Fat-containing liver lesions on imaging: detection and differential diagnosis. AJR Am J Roentgenol 210:68–77
doi: 10.2214/AJR.17.18136
pubmed: 29064755
Asayama Y, Nishie A, Ishigami K et al (2016) Fatty change in moderately and poorly differentiated hepatocellular carcinoma on MRI: a possible mechanism related to decreased arterial flow. Clin Radiol 71:1277–1283
doi: 10.1016/j.crad.2016.04.020
pubmed: 27210243
Yu J-S, Chung J-J, Kim JH, Kim KW (2007) Fat-containing nodules in the cirrhotic liver: chemical shift MRI features and clinical implications. AJR Am J Roentgenol 188:1009–1016
doi: 10.2214/AJR.06.0756
pubmed: 17377037
Aubé C, Oberti F, Lonjon J et al (2017) EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int 37:1515–1525
doi: 10.1111/liv.13429
pubmed: 28346737
Paisant A, Vilgrain V, Riou J et al (2020) Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. J Hepatol 72:937–945
doi: 10.1016/j.jhep.2019.12.011
pubmed: 31870951
Balci NC, Befeler AS, Bieneman BK, Fattahi R, Saglam S, Havlioglu N (2009) Fat containing HCC: findings on CT and MRI including serial contrast-enhanced imaging. Acad Radiol 16:963–968
doi: 10.1016/j.acra.2009.02.010
pubmed: 19386514
Inui S, Kondo H, Tanahashi Y et al (2021) Steatohepatitic hepatocellular carcinoma: imaging findings with clinicopathological correlation. Clin Radiol 76:160.e15-160.e25
doi: 10.1016/j.crad.2020.09.011
pubmed: 33046228
You M-W, Yun SJ (2019) Differentiating between hepatocellular carcinoma and intrahepatic cholangiocarcinoma using contrast-enhanced MRI features: a systematic review and meta-analysis. Clin Radiol 74:406.e9-406.e18
doi: 10.1016/j.crad.2018.12.016
pubmed: 30704667
Kadoya M, Matsui O, Takashima T, Nonomura A (1992) Hepatocellular carcinoma: correlation of MR imaging and histopathologic findings. Radiology 183:819–825
doi: 10.1148/radiology.183.3.1316622
pubmed: 1316622
Martín J, Sentís M, Zidan A et al (1995) Fatty metamorphosis of hepatocellular carcinoma: detection with chemical shift gradient-echo MR imaging. Radiology 195:125–130
doi: 10.1148/radiology.195.1.7892452
pubmed: 7892452
Taniai M, Hashimoto E, Tobari M et al (2018) Clinicopathological investigation of steatohepatitic hepatocellular carcinoma: a multicenter study using immunohistochemical analysis of adenoma-related markers: clinicopathological investigation of steatohepatitic hepatocellular carcinoma. Hepatol Res 48:947–955
doi: 10.1111/hepr.13203
pubmed: 30058778
Lee JS, Yoo JE, Kim H et al (2017) Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma. PLoS One 12:e0171922
doi: 10.1371/journal.pone.0171922
pubmed: 28273155
pmcid: 5342190
Luetkens JA, Kupczyk PA, Doerner J et al (2015) Respiratory motion artefacts in dynamic liver MRI: a comparison using gadoxetate disodium and gadobutrol. Eur Radiol 25:3207–3213
doi: 10.1007/s00330-015-3736-x
pubmed: 25903709